Market Access Analytics for Pharma: What to Measure, Build or Buy

What market access analytics is, in one paragraph

Market access analytics is the work of linking payer coverage, formulary status, prior authorization outcomes, rebates and patient starts so a pharma company can see whether the access it pays for actually turns into patients on therapy. Done well, it answers three questions every week: where is the product covered, where is that coverage being pulled through into approved and filled prescriptions, and what is each covered life costing in rebates and fees.

Most mid-sized manufacturers already hold the data. They license formulary data from a vendor such as MMIT or Fingertip, receive specialty pharmacy and hub feeds, and track contracts in spreadsheets. What they lack is the layer that joins those sources, so the access team reports coverage, the brand team reports prescriptions, finance reports gross to net, and no one can say which payer decisions moved the numbers.

This guide covers what market access analytics should measure, the data behind each measure, a worked pull-through example with numbers, the choice between a platform, a custom build or both, realistic timelines, and the mistakes that make access dashboards look busy without changing a decision. It sits within our specialty pharmacy analytics work and feeds the service described on our pharma commercial analytics consulting page.

Why market access analytics matters more in 2026

Three changes have made access the place where brand forecasts now break.

• Gross to net keeps widening in absolute terms. Drug Channels Institute estimated in July 2026 that manufacturers' total gross-to-net reductions for brand-name drugs reached $416 billion in 2025, and that manufacturers realised only about half of list prices. Across the eight large manufacturers it tracked, the unweighted average list price rose 3.7% in 2025 while the average net price fell 1.8%. When half the list price goes to rebates, fees and discounts, a coverage decision is also a pricing decision, and analytics that ignores net price measures the wrong thing.
• Medicare negotiation now reaches Part B. In January 2026 CMS selected 15 drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first Part B drugs, with negotiated prices effective 1 January 2028. CMS put their combined Medicare spending at about $27 billion. Brands on or near that list need Medicare scenarios, not a single national forecast.
• Cash prices now sit next to formulary prices. Pharmaceutical Commerce reported in August 2026 that TrumpRx, launched in February 2026, can place a manufacturer's cash price in front of a prescriber next to the plan's negotiated price through real-time benefit tools. Access teams now have to track a cash channel alongside the insured one.

Each of these makes the same demand: tie a payer decision to patients and net revenue at account level, quickly enough to act before the next contract cycle.

The questions market access analytics should answer

• Coverage and restrictions

  Where is the product covered, on which tier, and with what prior authorization, step therapy or quantity limits, by plan, channel and geography.

  • Covered lives by status
  • Restriction changes over time
  • Competitor position on the same plans

• Pull-through

  Whether coverage on paper turns into approved and filled prescriptions, by payer and by territory.

  • Approval rate on first submission
  • Time from referral to first fill
  • Territories under-pulling good coverage

• Gross to net by account

  What each contract costs in rebates, admin fees, chargebacks and copay support, and what net price remains per script.

  • Net price by payer
  • Accruals against actual invoices
  • Rebate cost on volume you would have had anyway

• Rejections and abandonment

  Why prescriptions fail: denials, missing paperwork, patient cost share, or a patient who never picked up.

  • Denial reasons by plan
  • Abandonment by out-of-pocket band
  • Appeals won and lost

• Policy scenarios

  What Medicare negotiation, 340B changes or a lost formulary position would do to volume and net revenue.

  • Medicare versus commercial mix
  • Best, base and worst cases
  • Exposure by account

• Field and FRM targeting

  Which offices and accounts need a field reimbursement manager or a payer account visit this week.

  • Offices with high denial rates
  • Accounts with new restrictions
  • Follow-up lists pushed to CRM

The data behind each question, and where it comes from

Market access analytics fails most often because one question needs four sources that use four different identifiers. Here is the usual map.

• Formulary and coverage data (licensed from vendors such as MMIT, part of Norstella, or Fingertip Formulary from Clarivate): tier, restrictions and covered lives by plan. The plan identifiers rarely match what your pharmacy and claims feeds use, so a payer hierarchy that rolls plans up to PBMs and parent organisations is the first thing to build.
• Specialty pharmacy and hub data: referrals, benefit verification, prior authorization status, approvals, denials and first fills. This is where pull-through is actually measured, and where status codes differ by pharmacy.
• Claims and prescription data: open or closed claims and syndicated prescription data show the wider market, including competitor share on the same plans.
• Contract, rebate and chargeback data: usually in a contracting system or spreadsheets owned by finance or trade. Needed for net price by account, as covered in our guide to gross to net in specialty pharma.
• CRM and territory alignment: Veeva or Salesforce activity and the zip-to-territory file, so access results can be shown per territory and acted on by the field.

If you can only fund one step, fund the identifiers: one plan master, one prescriber and account master, one product hierarchy. Every dashboard built on top of mismatched identifiers will be argued about rather than used.

Worked example: did the formulary win pay off?

The figures below are illustrative, chosen to show the arithmetic rather than to describe any real product. A specialty brand with a list price (WAC) of $6,000 per month moves from non-preferred to preferred status on a large commercial plan. To win it, the manufacturer raises the rebate on that plan from 20% to 32% of WAC.

Before the change, prescribers submit 800 new prescriptions a month for members of the plan. 52% are approved on first submission and 18% of approved scripts are abandoned at the pharmacy. Paid starts: 800 x 0.52 x 0.82 = 341. Net price per month of therapy: $6,000 less 20% = $4,800. Monthly net revenue from new starts: 341 x $4,800 = $1,636,800.

Three months after, submissions rise to 820, first-pass approval climbs to 78% because the prior authorization criteria were relaxed, and abandonment falls to 15% because cost share dropped. Paid starts: 820 x 0.78 x 0.85 = 544. Net price: $6,000 less 32% = $4,080. Monthly net revenue: 544 x $4,080 = $2,219,520.

The win added about $582,720 a month in net revenue from new starts, after paying the higher rebate on every script, including those that would have been written anyway. Splitting the 203 extra starts shows where it came from:

• Approval rate: 800 x (0.78 minus 0.52) x 0.82 = about 171 starts
• Lower abandonment: 800 x 0.78 x (0.85 minus 0.82) = about 19 starts
• More prescriptions written: 20 x 0.78 x 0.85 = about 13 starts

Most of the gain came from approvals, not from prescribers writing more. That points the next action at offices whose approval rate did not rise: if one territory sits at 74% approval on this plan and another at 61%, the second needs a field reimbursement visit, not more sales calls. A national prescription trend line would have shown a rise and hidden all of this.

Platform, custom build, or both: how to choose

• Buy a market access platform when

  Your main need is coverage intelligence: tracking formulary and policy changes across hundreds of plans, competitor positions and alerts.

  • Large plan footprint to monitor
  • Access team wants self-serve search
  • Little need to join with your own SP or contract data

• Build on your own licences when

  The questions depend on your data: pull-through, net price by account, abandonment by cost share, territory-level action lists.

  • Hub and SP feeds you already receive
  • Contract data held in spreadsheets
  • Definitions the vendor tool cannot change

• Combine them when

  Most mid-sized manufacturers land here: license coverage data from a vendor, then load it into your own warehouse next to SP, claims and contract data.

  • Vendor data as one input, not the whole answer
  • One plan master across all sources
  • Dashboards in the BI tool teams already use

Market access analytics platforms: cost and timelines

Platform pricing is rarely published. A 2026 comparison of twelve market access analytics platforms written by Tellius, itself a vendor, notes that most list custom pricing, and gives implementation estimates ranging from four to six weeks for its own product to eight to twelve weeks or longer for others. Treat any vendor's own figures as a starting point for questions, not a quote.

Four things drive the real cost, whichever route you take:

1. Data licences. Formulary, claims and prescription data are licensed separately, and the licence terms decide what you may load into which tool.
2. Number of sources to join. Each specialty pharmacy, hub and contract file adds mapping and checks. Three specialty pharmacies with different status codes is a different job from one.
3. Identifier quality. Clean plan and account masters make every later report cheaper. Poor ones make every report a reconciliation exercise.
4. Refresh frequency. A monthly access review needs less automation than a weekly pull-through view pushed to field teams.

On timing, a useful rule is to agree the first two or three reports during scoping and ship those before widening the scope. A pull-through view for one brand on a handful of priority plans comes first. Gross to net by account and policy scenarios follow once the masters are stable. If you are weighing outside support, our guide to outsourcing pharma commercial analytics sets out what to keep in house.

How we build market access analytics

Common mistakes in market access analytics

When not to invest in market access analytics yet

A dedicated build is not always the right next step. Hold off if the product is pre-launch and no SP or hub data exists yet; start with launch analytics planning instead and design the data feeds into your pharmacy contracts. Hold off if almost all volume sits with one or two payers that your account team already reviews line by line; a well-kept spreadsheet may be enough. And do not buy a platform to fix a data problem: if your plan identifiers do not match across sources, a new tool will show the mismatch in better colours.

The case for investing is strongest when you have several specialty pharmacies, a meaningful share of Medicare or Part B exposure, contracts renewing in the next cycle, and teams that disagree about what last quarter's access changes did. Our founder came up through pharma commercial operations consulting at ZS, and our case work for a specialty therapy provider cut manual reporting work by 60 to 80 percent once identifiers and pipelines were fixed. The same foundations carry market access analytics.

Market access analytics questions